A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone

Neoplasia

Volumn 9, Issue 12, 2007, Pages 1003-1011

  Lee, Kuei C ^a   Bradley, Deborah A ^a   Hussain, Maha ^a   Meyer, Charles R ^a   Chenevert, Thomas L ^a   Jacobson, Jon A ^a   Johnson, Timothy D ^b   Galban, Craig J ^a   Rehemtulla, Alnawaz ^a   Pienta, Kenneth J ^a   Ross, Brian D ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Androgen deprivation therapy; Diffusion MRI; Functional diffusion map; Imaging biomarker; Metastatic prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BIOLOGICAL MARKER; GOSERELIN; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BONE TUMOR; CASE REPORT; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION; FEASIBILITY STUDY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME;

EID: 37149021097     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07954     Document Type: Article

References (50)

1. American Cancer Society (2007). Cancer Facts & Figures 2007. American Cancer Society, Atlanta.
2. Taichman RS, Loberg RD, Mehra R, and Pienta KJ (2007). The evolving biology and treatment of prostate cancer. J Clin Invest 117 (9), 2351-2361.
3. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, and Kohli M (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (15), 1513-1520.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, and Turesson I (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (15), 1502-1512.
5. Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, and Rubens RD (1977). Assessment of response to therapy in advanced breast cancer. Br J Cancer 35 (3), 292-298.
6. Hayward JL, Carbone PP, Rubens RD, Heuson JC, Kumaoka S, and Segaloff A (1978). Assessment of response to therapy in advanced breast cancer (an amendment). Br J Cancer 38 (1), 201.
7. World Health Organization (1979). WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization Offset Publication, Atlanta.
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, and Christian MC (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (3), 205-216.
9. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, and Ueno NT (2004). Bone imaging in metastatic breast cancer. J Clin Oncol 22 (14), 2942-2953.
10. Bubley GJ, Carducci M, Dahut W, Dawson M, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, and Hudes G (1999). Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 (11), 3461-3467.
11. Ross BD, Chenevert TL, Kim B, and Ben-Yoseph O (1994). Magnetic resonance imaging and spectroscopy: application to experimental neuro-oncology. Q Magn Reson Biol Med 1, 89-106.
12. Chenevert TL, McKeever PE, and Ross BD (1997). Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 3 (9), 1457-1466.
13. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, and Ross BD (2000). Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92 (24), 2029-2036.
14. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, and Rehemtulla A (2000). Combined effect of tumor necrosis factor - related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 97 (4), 1754-1759.
15. Lee KC, Moffat BA, Schott AF, Layman R, Ellingworth S, Juliar R, Khan AP, Helvie M, Meyer CR, and Chenevert TL (2007). Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res 13 (2 Pt 1), 443-450.
16. Lee KC, Sud S, Meyer CR, Moffat BA, Chenevert TL, Rehemtulla A, Pienta KJ, and Ross BD (2007). An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res 67 (8), 3524-3528.
17. Moffat BA, Hall DE, Stojanovska J, McConville PJ, Moody JB, Chenevert TL, Rehemtulla A, and Ross BD (2004). Diffusion imaging for evaluation of tumor therapies in preclinical animal models. Magma 17 (3-6), 249-259.
18. Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, Quint DJ, Johnson TD, Junck L, Robertson PL, and Muraszko KM (2003). Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2 (6), 581-587.
19. Stegman LD, Rehemtulla A, Hamstra DA, Rice DJ, Jonas SJ, Stout KL, Chenevert TL, and Ross BD (2000). Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther 7 (12), 1005-1010.
20. 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 73 (1), 61-64.
21. 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther 10 (5), 916-928.
22. Lee KC, Hall DE, Hoff BA, Moffat BA, Sharma S, Chenevert TL, Meyer CR, Leopold WR, Johnson TD, and Mazurchuk RV (2006). Dynamic imaging of emerging resistance during cancer therapy. Cancer Res 66 (9), 4687-4692.
23. Lee KC, Hamstra DA, Bhojani MS, Khan AP, Ross BD, and Rehemtulla A (2007). Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res 13 (6), 1839-1846.
24. Lee KC, Hamstra DA, Bullarayasamudram S, Bhojani MS, Moffat BA, Dornfeld KJ, Ross BD, and Rehemtulla A (2006). Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit. Gene Ther 13 (2), 127-137.
25. Schepkin VD, Lee KC, Kuszpit K, Muthuswami M, Johnson TD, Chenevert TL, Rehemtulla A, and Ross BD (2006). Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance. NMR Biomed 19 (8), 1035-1042.
26. Chenevert TL, Meyer CR, Moffat BA, Rehemtulla A, Mukherji SK, Gebarski SS, Quint DJ, Robertson PL, Lawrence TS, and Junck L (2002). Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 1 (4), 336-343.
27. Hall DE, Moffat BA, Stojanovska J, Johnson TD, Li Z, Hamstra DA, Rehemtulla A, Chenevert TL, Carter J, and Pietronigro D (2004). Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res 10 (23), 7852-7859.
28. Jennings D, Hatton BN, Guo J, Galons JP, Trouard TP, Raghunand N, Marshall J, and Gillies RJ (2002). Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 4 (3), 255-262.
29. Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, and Gillies RJ (2005). Dynamic contrast - enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 7 (5), 475-485.
30. Theilmann RJ, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Moore J, Gillies RJ, and Stopeck A (2004). Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6 (6), 831-837.
31. Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, and Gillies RJ (1999). Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1 (2), 113-117.
32. 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase - mediated gene therapy in vivo: identification of apoptotic response. Cancer Res 58 (17), 3791-3799.
33. Poptani H, Puumalainen AM, Grohn OH, Loimas S, Kainulainen R, Yla-Herttuala S, and Kauppinen RA (1998). Monitoring thymidine kinase and ganciclovir - induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 5 (2), 101-109.
34. Ross BD, Zhao YJ, Neal ER, Stegman LD, Ercolani M, Ben-Yoseph O, and Chenevert TL (1998). Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study. Proc Natl Acad Sci USA 95 (12), 7012-7017.
35. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien C, Mukherji S, Quint DJ, and Gebarski SS (2005). Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102 (15), 5524-5529.
36. Moffat BA, Chenevert TL, Meyer CR, McKeever PE, Hall DE, Hoff BA, Johnson TD, Rehemtulla A, and Ross BD (2006). The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8 (4), 259-267.
37. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukherji SK, Quint DJ, Gebarski SS, Fan X, and Tsien CI (2005). Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA 102 (46), 16759-16764.
38. Meyer CR, Boes JL, Kim B, Bland PH, Zasadny KR, Kison PV, Koral K, Frey KA, and Wahl RL (1997). Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal 1 (3), 195-206.
39. Scher HI, Morris MJ, Kelly WK, Schwartz LH, and Heller G (2005). Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 11 (14), 5223-5232.
40. Scher HI, Warren M, and Heller G (2007). The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 13 (5), 1488-1492.
41. Fogelman I, Cook G, Israel O, and Van der Wall H (2005). Positron emission tomography and bone metastases. Semin Nucl Med 35 (2), 135-142.
42. Cook GJ and Fogelman I (2001). The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med 31 (3), 206-211.
43. Koizumi M, Matsumoto S, Takahashi S, Yamashita T, and Ogata E (1999). Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl Med 24 (1), 15-20.
44. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, and Laval-Jeantet M (1986). MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 161 (2), 401-407.
45. Hayashida Y, Yakushiji T, Awai K, Katahira K, Nakayama Y, Shimomura O, Kitajima M, Hirai T, Yamashita Y, and Mizuta H (2006). Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol 16 (12), 2637-2643.
46. Uhl M, Saueressig U, Koehler G, Kontny U, Niemeyer C, Reichardt W, Ilyasof K, Bley T, and Langer M (2006). Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas. Pediatr Radiol 36 (12), 1306-1311.
47. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, and Donnelly B (2006). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 (24), 3984-3990.
48. Koh DM and Collins DJ (2007). Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188 (6), 1622-1635.
49. Komori T, Narabayashi I, Matsumura K, Matsuki M, Akagi H, Ogura Y, Aga F, and Adachi I (2007). 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med 21 (4), 209-215.
50. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, and Van Cauteren M (2004). Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22 (4), 275-282.